Rossano Cesari

2.9k citations

34 papers · 2.1k indexed · h-index 20

Impact in

Genetics top 2%
- Chronic Lymphocytic Leukemia Research
- Genetics and Neurodevelopmental Disorders
Oncology top 5%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers

Papers in

Oncology 14
- PARP inhibition in cancer therapy 4
- CAR-T cell therapy research 3
Genetics 10
- Genetics and Neurodevelopmental Disorders 6

Co-authors: Carlo M. Croce George A. Calin Eric S. Martin Giandomenico Russo Susan A. Shinton Richard R. Hardy Anatoliy Koval Bo Huang
Journals: Clinical Cancer Research (6 papers)Proceedings of the National Academy of Sciences (5 papers)Journal of Clinical Oncology (4 papers)European Journal of Cancer (3 papers)Cancer Research (3 papers)
Partner nations: United States Italy Spain

In The Last Decade

Rossano Cesari

34 papers receiving 2.1k citations

Peers

Countries citing papers authored by Rossano Cesari

Since Specialization

Citations

This map shows the geographic impact of Rossano Cesari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rossano Cesari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rossano Cesari more than expected).

Fields of papers citing papers by Rossano Cesari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rossano Cesari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rossano Cesari. The network helps show where Rossano Cesari may publish in the future.

Co-authors

The 25 scholars most cited alongside Rossano Cesari, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rossano Cesari Line = papers co-authored together Rossano Cesari links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition Urologic Oncology Seminars and Original Investigations ·Jens Bedke, Peter C. Black, Bernadett Szabados, Félix Guerrero‐Ramos, Shahrokh F. Shariat, Évanguelos Xylinas, Julia Brinkmann, John A. Blake-Haskins, Rossano Cesari, Joan Palou Redorta	2023	9
2	A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Guérin, unresponsiv,e high-risk, non-muscle invasive bladder cancer: CREST Study Cohort B. Journal of Clinical Oncology ·Neal D. Shore, Thomas Powles, Jens Bedke, Matt D. Galsky, Evgeny Kopyltsov, Andrea Necchi, Joan Palou, Jennifer Vermette, Rizzo Holguín, Kristen J. Pierce, Rossano Cesari, Gary D. Steinberg	2022	2
3	Non-muscle-invasive bladder cancer: An overview of potential new treatment options Urologic Oncology Seminars and Original Investigations ·Neal D. Shore, Joan Palou Redorta, G. Robert, Thomas E. Hutson, Rossano Cesari, Hariharan Subramanian, Ó. Rodríguez Faba, Alberto Briganti, Gary D. Steinberg	2021	39
4	Abstract P1-19-03: JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts Cancer Research ·Timothy A. Yap, Panagiotis A. Konstantinopoulos, Melinda L. Telli, Smita Saraykar, J. Thaddeus Beck, Matthew D. Galsky, Jame Abraham, David R. Wise, Mustafa Khasraw, Gábor Rubovszky, Mikhail Dvorkin, Anil A. Joy, Mateusz Opyrchal, Daria Stypinski, Colombe Chappey, Ross Stewart, Rossano Cesari, Laura Pérez Alonso, Aditya Bardia	2020	15
5	JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect. Journal of Clinical Oncology ·David M. Hyman, Amelia Zelnak, Todd M. Bauer, Susanna V. Ulahannan, James M. Ford, Rossano Cesari, Margaret Hoyle, Colombe Chappey, Ross Stewart, Umberto Conte, Timothy A. Yap	2019	11
6	Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer Clinical Cancer Research ·Neil H. Segal, Aiwu Ruth He, Toshihiko Doi, Ronald Levy, Shailender Bhatia, Michael J. Pishvaian, Rossano Cesari, Ying Chen, Craig B. Davis, Bo Huang, Aron D. Thall, Ajay K. Gopal	2018	181
7	JAVELIN PARP medley: A phase Ib/II study of avelumab (anti–PD-L1) plus talazoparib in locally advanced or metastatic solid tumors Annals of Oncology ·Timothy A. Yap, J. Thaddeus Beck, Ross Stewart, Cucieru Valerian, Colombe Chappey, Rossano Cesari, Laura Pérez Alonso, Matt D. Galsky, David R. Wise	2018	5
8	Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor Annals of Surgical Oncology ·Víctor M. Villalobos, F. De Havilland Hall, Antonio Jimeno, Lia Gore, Kenneth A. Kern, Rossano Cesari, Bo Huang, Jeffrey Schowinsky, Soumendra Nath Bandyopadhyay, Brianna Hoffner, Anthony Elias, Wells A. Messersmith	2017	48
9	A PHASE I STUDY OF UTOMILUMAB (PF‐05082566), A 4‐1BB/CD137 AGONIST, IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH CD20⁺ NON‐HODGKIN'S LYMPHOMA Hematological Oncology ·Ajay K. Gopal, Ronald Levy, Roch Houot, Sandip Pravin Patel, Kiyohiko Hatake, Leslie Popplewell, Lilik Hikmawati, Craig B. Davis, Bo Huang, Rossano Cesari, Aron D. Thall, Adrian Woolfson, Nancy L. Bartlett	2017	8
10	A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors Clinical Cancer Research ·Andrew J. Wagner, Wells A. Messersmith, M. Naveed Shaik, Sherry Li, Xianxian Zheng, Karen R. McLachlan, Rossano Cesari, Rachel Courtney, Wendy J. Levin, Anthony B. El-Khoueiry	2014	61
11	A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014 Clinical Cancer Research ·Wells A. Messersmith, Geoffrey I. Shapiro, James M. Cleary, Antonio Jimeno, Arvind Dasari, Bo Huang, M. Naveed Shaik, Rossano Cesari, Xianxian Zheng, Jennifer M. Reynolds, Patricia A. English, Karen R. McLachlan, Kenneth A. Kern, Patricia LoRusso	2014	175
12	Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study BMC Cancer ·Thomas Bachelot, José Á. García-Sáenz, Sunil Verma, Maya Gutierrez, Xavier Pivot, Mark Kozloff, Catherine Prady, Xin Huang, Reza Khosravan, Zhixiao Wang, Rossano Cesari, Vanessa Tassell, Kenneth A. Kern, Jean‐Yves Blay, Aňa Lluch	2014	19
13	Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer The Breast ·Giuseppe Curigliano, Xavier Pivot, Javier Cortés, Anthony Elias, Rossano Cesari, Reza Khosravan, Mary Collier, Xin Huang, 正文竹内, Kenneth A. Kern, Aron Goldhirsch	2013	73
14	In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of β-thalassemia Proceedings of the National Academy of Sciences ·Annarita Miccio, Rossano Cesari, Francesco Lotti, Claudia Rossi, Francesca Sanvito, Maurilio Ponzoni, Samantha Routledge, Rojelly Br Payung, Michael Antoniou, Giuliana Ferrari	2008	117
15	HMGA1 protein is a novel target of the ATM kinase European Journal of Cancer ·Francesca Pentimalli, Dario Palmieri, Roberto Pacelli, Corrado Garbi, Rossano Cesari, Eric S. Martin, Giovanna Maria Pierantoni, Paolo Chieffi, Carlo M. Croce, Vincenzo Costanzo, Monica Fedele, Alfredo Fusco	2008	26
16	Tumor Suppressor Functions of ARLTS1 in Lung Cancers Cancer Research ·Sai Yendamuri, Francesco Trapasso, Manuela Ferracin, Rossano Cesari, Cinzia Sevignani, Masayoshi Shimizu, Shashi Rattan, Tamotsu Kuroki, Kristoffel R. Dumon, Florencia Bullrich, Chang‐Gong Liu, Massimo Negrini, Noel N. Williams, Larry R. Kaiser, Carlo M. Croce, George A. Calin	2007	13
17	Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models Cancer Gene Therapy ·Francesco Trapasso, Manuela Sarti, Rossano Cesari, Sai Yendamuri, Kristoffel R. Dumon, Rami I. Aqeilan, Francesca Pentimalli, Maria Luisa Cito, Hansjüerg Alder, Nobutsugu Abe, Takashi Watanabe, Giuseppe Viglietto, Carlo M. Croce, Alfredo Fusco	2004	24
18	Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines. PubMed ·Cinzia Sevignani, George A. Calin, Rossano Cesari, Manuela Sarti, Hideshi Ishii, Sai Yendamuri, Andrea Vecchione, Francesco Trapasso, Carlo M. Croce	2003	62
19	Lack of correlation between environmental or biological indicators of benzene exposure at parts per billion levels and micronuclei induction Environmental Research ·Francesco Saverio Violante, Luis Felipe Ortega Guevara, Anna Barbieri, Antonio Accorsi, Stefano Mattioli, Rossano Cesari, Carmela Fimognari, Patrizia Hrelia	2003	26
20	Micronuclei induction, cell cycle delay and apoptosis as markers of cellular stress caused by ursodeoxycholic acid in human lymphocytes Mutation Research/Genetic Toxicology and Environmental Mutagenesis ·Carmela Fimognari, Michael Nüsse, Rossano Cesari, Giorgio Cantelli‐Forti, Patrizia Hrelia	2001	15

About Rossano Cesari

Rossano Cesari is a scholar working on Oncology, Genetics, Oral Surgery, Cancer Research and Molecular Biology, having authored 34 papers that have together received 2.1k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (8 papers), Genetics and Neurodevelopmental Disorders (6 papers), PARP inhibition in cancer therapy (4 papers), Bladder and Urothelial Cancer Treatments (4 papers), Ubiquitin and proteasome pathways (3 papers), Advanced Breast Cancer Therapies (3 papers), Hedgehog Signaling Pathway Studies (3 papers) and CAR-T cell therapy research (3 papers). The work is most often cited by research in Genetics (438 citations), Oncology (664 citations), Immunology (443 citations), Cancer Research (268 citations) and Molecular Biology (1.1k citations). Rossano Cesari has collaborated with scholars based in United States, Italy and Spain. Frequent co-authors include Carlo M. Croce, George A. Calin, Eric S. Martin, Giandomenico Russo, Susan A. Shinton, Richard R. Hardy, Anatoliy Koval, Bo Huang, Francesco Trapasso and Francesca Pentimalli. Their work appears in journals such as Clinical Cancer Research, Proceedings of the National Academy of Sciences, Journal of Clinical Oncology, European Journal of Cancer and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact